Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
Wynne C, Balgos A, Li J, Hamilton P, Tirador L, Jaen AM, Mo C, Yue Z, Ma Y, Wang Q, Wen R, Yao Z, Yu J, Yao W, Zhang J, Zheng H, Hong K, Zhu F, Liu Y.
Wynne C, et al. Among authors: zheng h.
Infect Dis Ther. 2024 Jun 14. doi: 10.1007/s40121-024-00998-z. Online ahead of print.
Infect Dis Ther. 2024.
PMID: 38874695
No abstract available.